DND PharmaTech

DND PharmaTech FCF Margin

The Free Cash Flow Margin of DND PharmaTech (347850.KQ) as of Nov 4, 2026 is -493.38 %. In the previous year, Free Cash Flow Margin was -194.29 % — a change of 153.94% (lower).

FCF Margin

-493.38 %

YoY

153.94%

Last updated:

Free Cash Flow Margin of DND PharmaTech is 2025 -493.38 % . Free Cash Flow Margin of DND PharmaTech was 2024 -194.29 % . It decreases by 153.94% lower compared to the previous year.

The DND PharmaTech FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2021
-3,970.63 KRW
Jan 1, 2022
-8,811.85 KRW
Jan 1, 2023
-49.06 KRW
Jan 1, 2024
-194.29 KRW
Jan 1, 2025
-493.38 KRW
The DND PharmaTech FCF Margin history
YEARFCF MarginYoY
-493.38 %+153.94%
-194.29 %+296.04%
-49.06 %-99.44%
-8,811.85 %+121.93%
-3,970.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DND PharmaTech Stock analysis

What does DND PharmaTech do? DND PharmaTech Inc generates revenue primarily through its research and development activities focused on metabolic disease, neurodegenerative, and fibrotic diseases. The company develops therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis as part of its product pipeline. Clinical-stage biotech companies like DND PharmaTech typically secure funding through partnerships, grants, and potential future licensing agreements with pharmaceutical firms. The target segments include pharmaceutical companies seeking innovative drug candidates and healthcare providers interested in new treatment options for complex conditions. The company's product pipeline targets indications such as metabolic disease, neurodegenerative, and fibrotic diseases. Its research focuses on therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis. DND PharmaTech operates as a clinical-stage biotech firm, meaning it is developing drugs but has not yet commercialized them. The primary buyers of its R&D services and potential future products would be pharmaceutical companies looking to expand their portfolios with new therapies. DND PharmaTech Inc's business model centers on developing innovative treatments for high-need medical conditions. The firm's focus on metabolic disease, neurodegenerative, and fibrotic diseases positions it to address significant unmet medical needs. Its pipeline includes therapeutic medicines for diabetes, obesity, and nonalcoholic steatohepatitis, which are areas with growing market demand. The company's clinical-stage status indicates it is still in the development phase rather than commercial production. DND PharmaTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DND PharmaTech stock

Free Cash Flow Margin of DND PharmaTech is -493.38 % in 2025.

Free Cash Flow Margin of DND PharmaTech changed from -194.29 % to -493.38 %, representing a 153.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin DND PharmaTech since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's DND PharmaTech with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DND PharmaTech

All Key Metrics — DND PharmaTech